Health Condition 1: null- Hyperlipidemia
Conditions
Interventions
Intervention1: Narsimha a polyherbal forulation: Narsimha is an ayurvedic polyherbal formulation containing Comiphora mukul, Tinospora cordifolia, Curcuma longa, Trigonella foenum-graceum & piper nigr
Sponsors
Nisarga Biotech Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1) The subject of 30-70 years of age of either sex with established hyperlipidema 2) Free of obvious health problems as established by medical history and physical examination. 3) The subject willing to give written informed consent and willing to comply with study protocol. 4) The subject with following primary selection criteria: LDL-C concentration > 130 mg %; Triglyceride level > 150 mg/dl 5) The subject not receiving lipid lowering drugs at least 3 months prior to the recruitment.
Exclusion criteria
Exclusion criteria: 1) Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, thyroid dysfunction as determined by medical history, physical examination or laboratory test, which in the opinion of the investigator, might interfere with the study objectives. 2) Subject participating in other clinical trial or planned participation in another clinical trial during the present trial period. 3) The subject receiving anti-inflammatory or lipid-lowering medication such as statins or finofibrates. 4) The subject with diseases demanding continuous administration of B-blockers, calcium antagonists, hypoglycemic agents or diuretics. 5) History of a previous severe allergic reaction (generalized utricaria; angioedema or anaphylaxix). 6) History of chronic alcohol consumption and/or intravenous drug abuse. 7) Pregnant and lactating women. 8) History of contraceptive, hormone replacement therapy (HRT) or steroids since last 3 months. 9) Subjects with history of tuberculosis, HIV or malignancy. 10) Hypersensitivity to any component of the drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the efficacy of poly-herbal formulation â??Narsimhaâ?? in hyperlipidemic subjectsTimepoint: 90 and 120 days | — |
Secondary
| Measure | Time frame |
|---|---|
| To confirm the safety of poly-herbal formulation â??Narsimhaâ?? in hyperlipidemic subjects.Timepoint: 90 and 120 days | — |
Countries
India
Contacts
Public ContactDrAbhijeet Deshpande
Deenanath Mangeshkar Hospital & Research Centre, Pune
Outcome results
None listed